VA Drug Price Reporting: The Manufacturer’s Calculation Sets the Ceiling

Non FAMP drug price reporting fraud occurs when a manufacturer knowingly supplies false pricing information that causes federal healthcare purchasers to pay too much. The federal ceiling depends on a number the manufacturer reports. A false input can raise what the government pays, while failures in the Federal Supply Schedule contract can create a separate overcharge. Taxpayers pay the inflated bill for drugs bought for veterans’ health care. If you work in government pricing or federal contracting, you may understand the calculation behind a price everyone else simply sees on an invoice.

Non-FAMP and the Federal Ceiling Price

Non-FAMP is the non-Federal average manufacturer price. It supplies the starting number for the federal ceiling price, the maximum covered-drug price for the federal purchasers known as the Big Four. The manufacturer’s reported non-FAMP is confidential.

Those purchasers are the Department of Veterans Affairs, the Department of Defense, the Public Health Service, including the Indian Health Service, and the Coast Guard. Under the Veterans Health Care Act, the ceiling starts at 76% of non-FAMP, with an additional discount tied to the Consumer Price Index. Manufacturers report non-FAMP quarterly.

That puts the manufacturer on both sides of an important calculation. It sells the drug and supplies the price information used to limit what the government pays for it. When the reported input is inflated, applying the required percentage to that input produces an inflated ceiling. The discount printed on the calculation does not reveal whether the starting number was right.

The FSS Contract Carries Its Own Obligations

The Federal Supply Schedule is the contracting framework through which manufacturers must make covered drugs available under a master agreement. The federal ceiling price supplies a price limit. FSS listing and contract price reductions create additional obligations alongside that calculation.

For someone inside the business, those are different places to see a failure. A pricing calculation can be wrong. A covered drug can reach the contract late. A required price reduction can go unapplied. Each leaves a different comparison between what the manufacturer charged and what the government should have paid.

These commitments also reach beyond the VA account. The Veterans Health Care Act ties compliance to access to payment from Medicaid and the specified federal purchasers. Federal contracting and government price reporting belong in the same conversation even when different people inside the company handle them.

Where VA Drug Overcharges Arise

The VA Office of Inspector General documented non-FAMP calculation errors, late covered-drug additions and price-reduction-clause violations in its September 11, 2024 report. It summarized 15 reviews completed in fiscal years 2022 and 2023. The categories show how an overcharge can start in the price calculation or in the handling of the contract.

Non-FAMP Calculation Errors

The inspector general identified non-FAMP calculation errors involving four manufacturers. An insider who understands the underlying calculation can help explain how the reported number was produced and which products carried the error.

The useful comparison is the original calculation against the corrected one, tied to the period and product. A changed total tells part of the story. The calculation behind it can show which input or treatment changed, and whether the same problem reaches other reporting periods.

Late Addition of Covered Drugs

Late additions to FSS contracts involved ten manufacturers. Here the overcharge arose from when covered drugs were added to the contract.

The product’s contract history therefore matters alongside its price history. The date a covered drug should have been added, the date it was added and the purchases in between can explain the overcharge.

Required Price Reductions

The inspector general found price-reduction-clause violations in two of the three disclosures it reviewed in that category. That puts the contract’s required reduction at the center of the comparison.

For an insider, the useful question is what should have changed in the government’s price and when. The contract requirement, the event requiring a reduction and the prices actually charged belong together. A calculation team and a contracting team may each see only part of that sequence. We work with you to connect them.

Federal Ceiling Price Calculation and a Self-Disclosed Overcharge

A self-disclosed overcharge can grow when the VA examines the calculation and the transactions behind it. In the reviews the inspector general summarized, some manufacturers supplied estimates of approximately $53.3 million. The inspector general recommended that VA collect approximately $61.2 million. VA collected approximately $59.3 million.

The manufacturers had already come forward. Even their own corrections left the government with an understated bill.

For a pricing team, a correction has both a calculation and a reach. Which products did it cover? Which periods? Which contract obligations? Those questions connect the revised number to the money that changed hands. They are also how a limited correction can come into focus when someone inside the business knows the problem extends further.

Why the VA Audit Leaves Manufacturers Unnamed

The inspector general’s public report identifies manufacturers by numbers and withholds the individual contract reviews because they contain sensitive commercial information protected by the Trade Secrets Act. Its findings still identify the kinds of failures, the affected product counts and the overcharges.

That makes the public account useful to someone who recognizes the work. A calculation error and a late contract addition leave different records, even when the report does not publish the manufacturer’s name. The category tells a pricing or contracting employee which part of the business the finding concerns.

The public report describes the result. An insider may be able to explain the decision behind it: how the calculation was built, what the contract team understood, when the problem became known and why the correction covered the products or periods it did. If your company has already disclosed an overcharge or you recognize its work in the audit, talk with our whistleblower experts about what that means for your case.

Sanofi Pasteur Disclosed an Error and the VA Found It Went Back Further

In the Sanofi Pasteur VA pricing settlement, announced by the Justice Department on April 3, 2017, the vaccine business agreed to pay $19,868,194 to resolve alleged overcharges under two contracts.

Sanofi disclosed that it had incorrectly calculated federal ceiling prices for certain drugs from 2007 through 2011 and overcharged the VA. The VA inspector general investigated and determined that the error had produced overcharges going back to 2002.

The company identified the calculation problem. The investigation moved its starting point further back. For an employee familiar with earlier versions of a pricing calculation, that is a recognizable question: did the correction reach all the periods affected by the error?

Medicaid and 340B Use Different Price Calculations

Medicaid rebates use Average Manufacturer Price and Best Price. The federal ceiling price uses non-FAMP. Those distinctions matter when the same drug appears in several government programs and a pricing employee is trying to explain which calculation went wrong.

AMP and Best Price

Average Manufacturer Price generally measures prices paid to the manufacturer through the retail community pharmacy channel, including purchases through wholesalers and direct purchases by those pharmacies. Best Price measures the lowest available manufacturer price among eligible purchasers, with specified exclusions. VA and FSS prices are among the excluded categories.

The same sales records can therefore feed calculations that treat transactions differently. A pricing discrepancy has to be connected to the program whose payment it changed.

The 340B Ceiling Price

The 340B ceiling price is calculated from AMP minus the Medicaid unit rebate amount. It limits what eligible safety-net purchasers can be charged. The manufacturer reports the ceiling, and a misstatement affecting the Medicaid rebate can also raise what those purchasers pay.

What Evidence Is Needed to Prove Fraud?

The useful evidence connects the drug, the pricing calculation or contract obligation, the amount charged and what the company knew. We assess how the pricing discrepancy and the decisions behind it fit together.

Original and corrected worksheets, contract histories and prices charged are records we help connect to the overcharge and the decisions behind it.

A disclosure and the VA’s review add another comparison: what the company said it had found against what the government concluded after examining it. An employee may understand why the disclosure covered particular products, contracts or periods. That knowledge can give meaning to a difference that otherwise appears only as a revised total.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

When You Know How the Price Was Chosen

If you work with non-FAMP calculations, FSS contracts or overcharge corrections, speak with our whistleblower experts about the pricing decisions you can explain. We work beside you to build your strongest pharmaceutical pricing whistleblower case around the affected drugs, government payments and decisions inside the company. We bring in pharmaceutical pricing whistleblower lawyers who understand federal purchasing and stay with you through the process.